Parvovirus, Erythema Infectiosum, and Pregnancy

PEDIATRICS ◽  
1990 ◽  
Vol 85 (1) ◽  
pp. 131-133
Author(s):  

Recent outbreaks of erythema infectiosum (fifth disease) have caused consternation among pregnant women and their physicians, because of the risk of spontaneous abortion caused by this viral infection. This statement contains information concerning the infection and recommendations regarding control of exposure. The agent of erythema infectiosum is a single-stranded DNA virus called parvovirus B19, which infects humans only.1,2 Parvovirus B19 is principally transmitted by respiratory secretions,3 and a primary site of replication is the red blood cell precursors found in the bone marrow.4 After an incubation period of approximately 1 week's duration, the virus produces a febrile illness accompanied by reticulocytopenia, which lasts approximately 7 days.5 The normal person recovers without evident anemia and, in some cases, within another week, a distinctive rash, consisting of a slapped cheek appearance and an erythematous, lacy rash on the trunk and extremities, will develop. Atypical maculopapular rashes also occur.6 In adult patients, particularly women, arthralgia or arthritis may develop at this stage7,8; children infrequently experience joint involvement. Asymptomatic infection without rash may occur more frequently than illness with typical rash. Infection with parvovirus B19 can also cause aplastic crisis in patients with red blood cell abnormalities leading to shortened red blood cell halflives (such as sickle cell disease and autoimmune hemolytic anemia). The aplastic crises develop approximately 1 week after onset of the acute illness due to parvovirus B19.9 Patients with aplastic crisis appear to be contagious from the onset or before the onset of acute illness and through the subsequent week or so.

Transfusion ◽  
2017 ◽  
Vol 57 (6) ◽  
pp. 1414-1418 ◽  
Author(s):  
Keiki Nagaharu ◽  
Yuka Sugimoto ◽  
Yuji Hoshi ◽  
Takanori Yamaguchi ◽  
Ryugo Ito ◽  
...  

2011 ◽  
Vol 50 (20) ◽  
pp. 2379-2382 ◽  
Author(s):  
Yuiko Tsukada ◽  
Kenji Yokoyama ◽  
Akaru Ishida ◽  
Makoto Handa ◽  
Takehiko Mori ◽  
...  

1997 ◽  
Vol 16 (11) ◽  
pp. 1093-1095 ◽  
Author(s):  
Kosuke Higashida ◽  
Kisho Kobayashi ◽  
Kanji Sugita ◽  
Naoko Karakida ◽  
Yoshiko Nakagomi ◽  
...  

Transfusion ◽  
2011 ◽  
Vol 51 (1) ◽  
pp. 129-136 ◽  
Author(s):  
Michael Kai Hourfar ◽  
Uschi Mayr-Wohlfart ◽  
Anna Themann ◽  
Walid Sireis ◽  
Erhard Seifried ◽  
...  

2021 ◽  
Vol 14 (1) ◽  
pp. e237393
Author(s):  
Olivia Janssen ◽  
Jing Lin

Congenital parvovirus B19 infection is a rare but serious condition that can result in hydrops fetalis and fetal death. Due to the virus’ cytotoxic effect on fetal red blood cell precursors, postnatal infection can cause a neonatal viremia and secondary pure red cell aplasia. Here, we describe a case of congenital parvovirus infection in a preterm infant complicated by hydrops fetalis and chronic anaemia that responded to postnatal treatment with intravenous immunoglobulin administered on day of life 44. After treatment, the anaemia resolved as the neonate exhibited interval increases in haemoglobin, haematocrit and reticulocyte count with no subsequent need for red blood cell transfusions.


2014 ◽  
Vol 86 (12) ◽  
pp. 2102-2106 ◽  
Author(s):  
Aki Ishikawa ◽  
Yuko Yoto ◽  
Takeshi Tsugawa ◽  
Hiroyuki Tsutsumi

2003 ◽  
Vol 36 (2) ◽  
pp. 229-233 ◽  
Author(s):  
Jean‐Francois Viallard ◽  
Marie Parrens ◽  
Olivier Hermine ◽  
Jean‐Michel Boiron ◽  
Marie‐Edith Lafon ◽  
...  

Author(s):  
M. A. Yermalovich ◽  
G. V. Semeiko ◽  
E. O. Samoilovich

Human parvovirus infection is characterized by a variety of clinical manifestations. Based on the genetic analysis, genotypes 1a, 1b, 2, 3a, 3b of parvovirus B19 are distinguished, which have different geographical distribution. In the period 2005–2016, in Belarus 210 strains of parvovirus B19 isolated from the patients with various forms of parvovirus infection, mainly erythema infectiosum, were genotyped. All strains, except one, belonged to genotype 1a. One strain belonged to genotype 3b and was isolated from a child with aplastic crisis who arrived in Belarus from Kazakhstan for medical care. On the phylogenetic tree, the strains of genotype 1a formed two groups related to the subtypes 1a1 and 1a2. During the 12-year observation, both subtypes circulated in Belarus, but with varying intensity. In the highest incidence years, as well as one or two years before and after this (2005–2008 and 2013–2016), strains of subtype 1a2 predominated in circulation. During the period of low incidence (2009–2012), the dominant position belonged to subtype 1a1. The average genetic distance inside each subtype was 0.51 % for 1a1 and 0.56 % for 1a2. Between subtypes it was also small – 1.32 %. It can be assumed that subtype 1a2 is more new for Belarus and therefore might be connected with the increase of morbidity.


Author(s):  
Ishan Patel ◽  
Mihir Odak ◽  
Steven Douedi ◽  
Abbas Alshami ◽  
Vandan Upadhyaya ◽  
...  

Background: Patients with sickle cell disease can experience various crises including sequestration crisis, haemolytic crisis and aplastic crisis. Due to alloantibody formation, transfusion alloantibodies can cause a haemolytic crisis. Treatment involves avoiding packed red blood cell transfusions, as well as intravenous immunoglobulin, steroids and eculizumab to decrease the chances of haemolysis. Case description: We report the case of a 42-year-old man who was found to have worsening anaemia after packed red blood cell transfusion with evidence suggestive of haemolytic crisis. Due to reticulocytopenia, aplastic crisis was also suspected and later confirmed via parvovirus IgG and IgM titres. The patient did not improve with steroid and intravenous immunoglobulin therapy and was treated with eculizumab as a salvage therapy. Conclusion: Concurrent hyper-haemolytic crisis and aplastic crisis should be suspected in patients with features of haemolysis and reticulocytopenia. Prompt recognition and treatment with eculizumab are paramount in those who fail steroid and intravenous immunoglobulin treatment.


Sign in / Sign up

Export Citation Format

Share Document